About
The Winslow philosophy
Company background
Our associates
Careers at Winslow
News
Commentary library
Philanthropy at Winslow
Spotlight on Winslow
Contact
Contact us
Contact associates
Directions – Boston
Directions – Braintree, MA
Directions – New York City
Directions – Paramus, NJ
Account Login
Account Resources
Cybersecurity
Tax Form Downloads to TurboTax®
Important information for investors
INDIVIDUAL INVESTORS
+ What approach is right for me?
+ Choosing a financial professional
+ Brokers
+ Investment advisors
+ The Winslow philosophy
+ Plan for life
+ What to expect: Six steps
+ Plan for retirement
+ Save for college
+ Invest and trade
+ Tax-advantaged investing
+ Trading desk services
+ Client support
+ Insure your future
+ Life insurance
+ Annuities: “Income for life”
+ Property and casualty
+ Submit your current policy
+ Long-term care
INSTITUTIONAL INVESTORS
+ Equity trading
+ Fixed income
+ Municipal desk
FIND AN ADVISOR
+ by Name
+ by Branch
OPPORTUNITIES AT WINSLOW
+ Financial advisors
+ Business partners
+ Working with Winslow
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaneck Biotech ETF
(NQ:
BBH
)
146.35
+1.40 (+0.97%)
Official Closing Price
Updated: 4:15 PM EDT, May 26, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vaneck Biotech ETF
Progenity Is Unlikely to Live Up to Its IPO Hype
December 15, 2021
Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech?
Via
InvestorPlace
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone
November 01, 2021
After the formidable run, NVAX stock has come under significant pressure, but between its pipeline and its Covid vaccine, it is a dip buy.
Via
InvestorPlace
Take A Look At The Top-Performing Biotech ETFs YTD
October 02, 2021
The biotechnology sector has been grabbing the headlines on the new coronavirus vaccine and drug-related updates. The space has also kept its promise of generating returns, with the Nasdaq...
Via
Talk Markets
Exposures
COVID-19
Biotech ETFs To Benefit From Latest Booster Update
August 21, 2021
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from...
Via
Talk Markets
Exposures
COVID-19
ETF Investing Areas to Consider for August
August 09, 2021
There is no doubt that the second-quarter 2021 earnings season is going strong.
Via
Talk Markets
Moderna ETFs To Rise On Positive COVID-19 Vaccine Updates
July 03, 2021
The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to...
Via
Talk Markets
Exposures
COVID-19
5 Top ETFs With Exposure To Biogen
June 07, 2021
Here is a look at five ETFs with large exposure to Biogen shares.
Via
Talk Markets
5 Top ETFs With Exposure To Biogen
June 07, 2021
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...
Via
Benzinga
Exposures
Product Safety
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines
May 08, 2021
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from...
Via
Talk Markets
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Stock Moves After Q1 Print: Technical Levels For The COVID-19 Vaccine Play
May 06, 2021
Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the...
Via
Benzinga
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Market Action
Symbol Lookup
MARKET NEWS